Inhibition of 3-hydroxy-3-methylglutarylcoenzyme a reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells

35Citations
Citations of this article
41Readers
Mendeley users who have this article in their library.

Abstract

The endocannabinoid system regulates cell proliferation in human breast cancer cells. Recently, we described that a metabolically stable anandamide analog, 2-methyl-2′-F-anandamide, by activation of CB1 receptors significantly inhibited cell proliferation of human breast cancer cell lines. In this study, we observed that the activation of the CB1 receptor, in two human mammary carcinoma cell lines, MDA-MB-231 and MCF7, caused the inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity due to a reduction of HMG-CoA reductase transcript levels. The decrease of HMG-CoA reductase activity induced the inhibition of the prenylation of proteins, in particular of the farnesylation of Ras oncogenic protein involved in cell proliferation of these cell lines. We suggest that the inhibitory effect of anandamide analog on tumor cell proliferation could be related to the inhibition of Ras farnesylation. © 2010 Society for Endocrinology.

Cite

CITATION STYLE

APA

Laezza, C., Malfitano, A. M., Proto, M. C., Esposito, I., Gazzerro, P., Formisano, P., … Bifulco, M. (2010). Inhibition of 3-hydroxy-3-methylglutarylcoenzyme a reductase activity and of Ras farnesylation mediate antitumor effects of anandamide in human breast cancer cells. Endocrine-Related Cancer, 17(2), 495–503. https://doi.org/10.1677/ERC-10-0009

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free